StreetInsider.com News Articles

Denali Therapeutics Inc. (DNLI) PT Raised to $35 at B.Riley

Tue, 25 Aug 2026 08:29:20 -0400

B.Riley analyst Marank Mamtani raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $35.00 (from $30.00) while maintaining a Buy rating.

Form 4 Denali Therapeutics Inc. For: Aug 12 Filed by: Watts Ryan J.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932101.html

Form 4 Denali Therapeutics Inc. For: Aug 12 Filed by: Watts Ryan J.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932101.html

Form 4 Denali Therapeutics Inc. For: Aug 11 Filed by: Schuth Alexander O.

Thu, 13 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26922545.html

Form 4 Denali Therapeutics Inc. For: Aug 11 Filed by: Schuth Alexander O.

Thu, 13 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260813/26922545.html

Form 144 Denali Therapeutics Inc. Filed by: Schuth Alexander O.

Tue, 11 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260811/26907271.html

Form 144 Denali Therapeutics Inc. Filed by: Schuth Alexander O.

Tue, 11 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260811/26907271.html

Denali Therapeutics Inc. (DNLI) PT Raised to $34 at UBS

Fri, 07 Aug 2026 09:58:33 -0400

UBS analyst Michael Yee raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $34.00 (from $25.00) while maintaining a Buy rating.

Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 4c

Thu, 06 Aug 2026 17:41:23 -0400

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.68), $0.04 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.6 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

Form 10-Q Denali Therapeutics Inc. For: Jun 30

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883857.html

Form 10-Q Denali Therapeutics Inc. For: Jun 30

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883857.html

Form 8-K Denali Therapeutics Inc. For: Aug 06

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883402.html

Form 8-K Denali Therapeutics Inc. For: Aug 06

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883402.html

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:01:00 -0400

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue
Advanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical development
$195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion
Conference call and webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2026, and

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:01:00 -0400

Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue
Advanced TransportVehicle™ portfolio with two Alzheimer’s disease programs now in clinical development
$195 million in gross proceeds received in July 2026 from sale of a Priority Review Voucher, bringing pro forma cash, cash equivalents and marketable securities to more than $1.1 billion
Conference call and webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2026, and

Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: BAILLIE GIFFORD & CO

Tue, 04 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260804/26863055.html

Form SCHEDULE 13G/A Denali Therapeutics Inc. Filed by: BAILLIE GIFFORD & CO

Tue, 04 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260804/26863055.html

Form 8-K Denali Therapeutics Inc. For: Jul 27

Tue, 28 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26821587.html

Form 8-K Denali Therapeutics Inc. For: Jul 27

Tue, 28 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26821587.html

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Mon, 27 Jul 2026 16:01:00 -0400

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June 30, 2026, on Thursday, August 6, 2026.

Following the announcement, Denali's management will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss Denali’s second quarter 2026 financial results and provide a general business update.

The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

Mon, 27 Jul 2026 16:01:00 -0400

The live webcast, along with an accompanying slide presentation, may be accessed through the Investors section of

Denali Therapeutics Inc. (DNLI) PT Raised to $36 at Morgan Stanley

Thu, 23 Jul 2026 08:43:09 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $36.00 (from $35.00) while maintaining a Overweight rating.

Denali Therapeutics Inc. (DNLI) PT Raised to $35 at Deutsche Bank

Fri, 17 Jul 2026 07:17:00 -0400

Deutsche Bank analyst David Hoang raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $35.00 (from $31.00) while maintaining a Buy rating.

Denali Therapeutics (DNLI) call put ratio 1.3 calls to 1 put as share price up 2.2%

Mon, 13 Jul 2026 14:20:17 -0400

Denali Therapeutics (NASDAQ: DNLI) 30-day option implied volatility is at 85; compared to its 52-week range of 53 to 118. Call put ratio 1.3 calls to 1 put as share price up 2.2%.

JPMorgan Resumes Denali Therapeutics Inc. (DNLI) at Overweight

Mon, 13 Jul 2026 03:14:33 -0400

JPMorgan analyst Jessica Fye resumes coverage on Denali Therapeutics Inc. (NASDAQ: DNLI) with a Overweight rating and a price target of $29.00.

The analyst comments: “We are moving to an Overweight rating and $29 December 2027 price target for DNLI shares. With the recent approval of Avlayah for Hunter syndrome, DNLI has transitioned to a commercial biotech, and we see the possibility of accelerated approval as soon as YE27 for DNL126 in Sanfillippo type-A (MPS IIIA). Beyond these lead rare disease programs, we see a rich pipeline advancing with multiple readouts over the next 12-18 months including 1) DNL593 for FTD,